Quizartinib
VANFLYTA (quizartinib) is an oral prescription tablet developed by Daiichi Sankyo Inc. for treating certain blood cancers. It works as a kinase inhibitor targeting FLT3 mutations, available in 17.7 mg and 26.5 mg strengths. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | VANFLYTA (quizartinib) is an oral prescription tablet developed by Daiichi Sankyo Inc. for treating certain blood cancers. It works as a kinase inhibitor targeting FLT3 mutations, available in 17.7 mg and 26.5 mg strengths. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Quizartinib",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Quizartinib — ANDA 216993 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216993"
}
]
|
| identifier | ANDA216993 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-safety",
"fda",
"health-care",
"prescription-drugs"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Quizartinib |
